Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017

Pernix Therapeutics Holdings, Inc. reports financial results for the quarter ended December 31, 2016.

Highlights

  • Summary numbers: Revenues of USD 30.17 million, Net Earnings of USD -86.08 million.
  • Gross margins narrowed from 7.90% to 1.37% compared to the same period last year, operating (EBITDA) margins now -16.59% from 11.05%.
  • Change in operating cash flow of 265.78% compared to same period last year is about the same as change in earnings, likely no significant movement in accruals or reserves.
  • Narrowing of operating margins contributed to decline in earnings.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31
Relevant Numbers (Quarterly)
Revenues (mil) 30.17 41.47 36.75 32.47 46.37
Revenue Growth (%YOY) -34.93 -14.7 -21.78 -4.19 -13.87
Earnings (mil) -86.08 -26.44 -31.14 -25.94 -81.67
Earnings Growth (%YOY) -5.4 -146.16 3.4 -9.55 -944.46
Net Margin (%) -285.28 -63.76 -84.74 -79.88 -176.12
EPS -8.59 -2.99 -4.7 -4.2 -13.4
Return on Equity (%) N/A N/A N/A -497.48 -446.77
Return on Assets (%) -100.59 -27.22 -29.24 -21.6 -58.88

Access our Ratings and Scores for Pernix Therapeutics Holdings, Inc.

Market Share Versus Profits

Revenues History
Earnings History

Compared to the same period last year, PTX-US‘s change in revenue was close to the amount of its change in earnings. It remains to be seen how the rest of its peer group’s results will turn out and if PTX-US‘s performance is a sign of any major shift in the composition of market share in this sector. Also, for comparison purposes, revenues changed by -27.24% and earnings by -225.58% compared to the previous period.

Earnings Growth Analysis

The company’s year-on-year decline in earnings was influenced by a weakening in gross margins from 7.90% to 1.37%, as well as issues with cost controls. As a result, operating margins (EBITDA margins) went from 11.05% to -16.59% in this time frame. For comparison, gross margins were 23.94% and EBITDA margins were 16.33% in the previous period.

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

PTX-US‘s decline in gross margins were offset by some improvements on the balance sheet. The management of working capital, for example, shows progress. The company’s working capital days have fallen to 9.71 days from 68.35 days for the same period last year. This leads Capital Cube to conclude that the gross margin decline is not altogether bad.

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

PTX-US‘s year-on-year change in operating cash flow of 265.78% is around its change in earnings. This suggests that there are likely no significant movement in accruals or reserves for managing earnings this period.

Margins

The company’s decline in earnings has been influenced by the following factors: (1) Decline in operating margins (EBIT margins) from -49.77% to -85.33% and (2) one-time items that contributed to a decrease in pretax margins from -131.09% to -283.91%

EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Pernix Therapeutics Holdings, Inc.

Company Profile

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla. The company was founded on March 9, 2010 and is headquartered in The Woodlands, TX.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of PTX-US.